← peptides typeshit

Novo Nordisk sets 2030 targets as GLP-1 rivals close in on Wegovy and Ozempic

The plan leans on pipeline drugs CagriSema and zenagamtide to diversify the business, with late stage trial results as the next test.

Read at Yahoo Finance

Recap by typeshit. Full story at Yahoo Finance.